Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$0.54 USD
-0.02 (-2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.54 0.00 (-0.44%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Century Therapeutics, Inc. has a market cap of $48.08M, which represents its share price of $0.56 multiplied by its outstanding shares number of 86.16M. As a small-cap company, IPSC's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IPSC 0.54 -0.02(-2.80%)
Will IPSC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPSC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSC
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
IPSC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Other News for IPSC
Century Therapeutics files $200M mixed shelf offering
Century Therapeutics (IPSC) Files for $200M Mixed Securities Offering | IPSC Stock News
Century Therapeutics files $200M mixed securities shelf
Century Therapeutics Holds 2025 Annual Stockholders Meeting
Leerink Partners Keeps Their Buy Rating on Century Therapeutics (IPSC)